🎈 Up Big Today: Find today's biggest gainers with our free screenerTry Stock Screener

Conagra Brands targets GLP-1 users with new labels - WSJ

Published 12/12/2024, 10:10 PM
© Reuters.
CAG
-

Conagra Brands (NYSE:CAG), a major player in the packaged-foods industry, is introducing a new label for a selection of its Healthy Choice frozen meals, branding them as "GLP-1 friendly," according to report from the Wall Street Journal. This initiative, starting in January, aims to cater to consumers who are reducing their food intake, particularly those using GLP-1 drugs like Ozempic and Wegovy for weight loss.

The label will be featured on 26 Healthy Choice products known for their high-protein, low-calorie, and good fiber content. These dietary qualities align with the needs of GLP-1 drug users, who often adjust their diets to include more protein and fiber to manage muscle mass and digestive health.

Bob Nolan, Conagra's senior vice president of demand science, expressed the company's intent to support this significant consumer demographic and establish a strong brand connection. Conagra's strategy comes at a time when the company is navigating a sales downturn due to consumers' pushback against rising grocery prices. Efforts to attract customers back to frozen meals have included promotions, product launches, and advertising campaigns to enhance frozen-vegetable sales.

While Conagra's packaging will explicitly mention the GLP-1 friendly aspect, other food companies have also developed products tailored to the dietary needs of weight-loss drug users without directly referencing the medications. Nestlé introduced Vital Pursuit, a line of frozen meals with nutritional value highlighted on the packaging. Abbott Laboratories (NYSE:ABT) launched a high-protein shake aimed at GLP-1 users, with packaging that emphasizes weight loss and muscle health.

The Healthy Choice brand, originating in the 1980s for those with heart conditions, is adapting to the growing use of weight-loss medications. Conagra executives noted that the adoption of GLP-1 drugs has had a slightly positive effect on their business, driven by the demand for frozen single-serve meals and appetizers that offer convenience and controlled portions.

The impact of weight-loss drugs is also being observed by other food manufacturers. Hershey CEO Michele Buck acknowledged a mild effect on their business and emphasized the importance of monitoring eating behaviors to adapt their product offerings accordingly.

Conagra has navigated regulatory processes to ensure the new labeling meets standards. After submitting concepts to the USDA and incorporating feedback, the company received approval in October for the new labels. Marketing efforts for the GLP-1 friendly meals are set to include social media campaigns, and the label may extend to additional Conagra products in the future.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.